Boehringer Ingelheim's alliance with digital health company Brainomix on an AI-enabled tool for diagnosing interstitial lung ...

Embattled UK Prime Minister Sir Keir Starmer has put changes to the health service on the legislative programme in today's ...

A drug at the heart of AstraZeneca's takeover of Amolyt has hit the mark in a phase 3 trial, but could be undermined by an ...

South Korea has designated life sciences and biotechnology as priority areas for growth and leadership. The country is experiencing rapid growth in biotechnology thanks to continuous public and ...

Henry Gosebruch, pictured here during his time at Neumora, is replacing Paul Stoffels as CEO of Galapagos. Just a few months after announcing a plan to separate its drug and cell therapy businesses ...

Texas Attorney General Ken Paxton has filed a lawsuit against Sanofi, claiming the company bribed doctors to prescribe its medicines, in the state's latest broadside against pharma groups. The ...

Already approved for lupus nephritis, Roche's Gazyva could be heading for broader use in the potentially life-threatening autoimmune disorder after clearing a phase 3 trial. The results of the ...

It turns out that the pause on shipments of Sarepta's Duchenne muscular dystrophy (DMD) gene therapy Elevidys over safety concerns has been short-lived. The FDA's request to suspend distribution of ...

Sanofi has called time on breast cancer candidate amcenestrant – at one time one of its top pipeline prospects – after it missed the mark in another clinical trial. The decision to abandon development ...

Isomorphic Labs' chief executive, Sir Demis Hassabis, delivering his Nobel Prize lecture in 2024. Alphabet-backed start-up Isomorphic Labs has added to the lustre attached to its AI-powered drug ...

Novo Nordisk is planning to open an artificial intelligence (AI) research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations. The Danish ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in non-muscle invasive bladder cancer (NMIBC). Top-line results from the ...